Abstract. Motility-related protein-1 (CD9), a type of cell surface glycoprotein comprising a four-pass transmembrane domain that forms multimeric complexes with other cell surface proteins, belongs to the tetraspanins family. From previous studies, we know that CD9 is considered to function primarily as a progression and metastasis suppressor in a variety of cancers, including breast, non-small cell lung colon and myeloma. However, an expanding body of literature has shown the contradictory outcome that tetraspanin CD9 is also vital in promoting cancer progression in several types of cancer. This review summarizes the recent studies on CD9 and concludes that it does not always act as a progression and metastasis suppressor. Conversely, in specific cases, CD9 may promote tumor progression through the following three aspects: Facilitating tumor cell transmigration, increasing tumor cell motility and hastening the growth of some cancers. In addition, CD9 appears to be an important marker of cancer stem cells in certain types of tumor.

Contents

1. Introduction
2. CD9 may facilitate tumor cell transmigration
3. CD9 may enhance tumor cell motility
4. CD9 contributes to the proliferation and survival of tumor cells
5. CD9 and cancer stem cells (CSCs)
6. Conclusion

1. Introduction

Tetraspanins are a family of integral proteins comprising 33 members, including the CD9, CD81, CD63 and CD151 proteins. They have been identified in mammalian cells and appear to be associated with a variety of cancer types (Table I) (1,2). Tetraspanins are membrane proteins containing a four-pass transmembrane domain, short N- and C-terminal cytoplasmic domains, a small intracellular loop, a small extracellular loop and a large extracellular loop (LEL). LELs may be subdivided into a constant region, which accounts for dimerization, and a variable region, which contains sites for interactions with non-tetraspanin partner molecules (1,3).

The tetraspanin CD9 gene is located on chromosome 12p13.3, coding a cell surface glycoprotein which belongs to the tetraspanin family and is expressed at a molecular mass of 25 and 28 kDa (4,5). CD9, also known as motility-related protein-1, was first identified as an antigen on lymphohematopoietic cells. Later, it was confirmed to be widely expressed in the plasma membrane of various normal cells, including smooth muscle, fibroblasts and several tumor cells (6-8). Similar to other tetraspanins, CD9 has been shown to be involved in a number of biological functions, such as cell adhesion, motility, cell migration, proliferation and differentiation (8-10). Numerous previous experimental studies and clinical results have demonstrated that CD9 functions as a progression and metastasis suppressor in several tumors. In addition, the downregulation of CD9 is tightly associated with a poor prognosis in breast cancer, non-small-cell lung cancer, colon cancer and multiple myeloma (11-14). The inactivation of CD9 may be due to epigenetic modifications, such as DNA methylation or histone deacetylation (14). A concept was gradually formed by previous studies that CD9 may selectively hamper several metastasis-promoting processes, including tumor cell motility, epithelial mesenchymal transition and recruitment of a protective environment (1). However, CD9 is not strictly classifiable as a metastasis and progression suppressor as several previous studies have confirmed that CD9, to some extent,
contributes to the progression and metastasis of other types of malignances (15-18). Such a contradictory phenomenon reflects the complexity of CD9, which may vary with types of tumor and may also depend on different molecules in the tetraspanin web (5,19-21). The current review discusses the latent mechanism of CD9 in promoting the progression and metastasis of several malignancies.

2. CD9 may facilitate tumor cell transmigration

Previous examination of CD9 expression in certain cancers, including breast and colon cancers, has shown that metastases reduce CD9 levels compared with primary tumors (22,23). Nevertheless, an increasing number of studies have suggested that CD9 may be markedly associated with tumor endothelial cell (EC) interactions during transendothelial invasion. In breast cancer, differential gene profiling revealed that the expression of CD9 was higher in metastatic cancer cells when compared with that of the corresponding primary tumor cells, despite that in the majority of cases, expression of motility-related protein-1 (MRP-1/CD9) was downregulated in metastatic carcinoma cells (24). In addition, CD9 was significantly overexpressed in bone metastases versus primary tumors (25). In the light of a murine myeloma model conducted by De Bruyne et al who observed marked local expression of CD9 in myeloma cells in contact with bone marrow ECs, CD9 was found to possibly mediate homing and/or spreading of the breast cancer cells through interaction with ECs (15). In cervical cancer, CD9 expression is downregulated in the majority of invasive cervical carcinomas, but is locally re-expressed at the site of invasion into blood or lymphatic vessels. Sauer et al hypothesized that CD9 may be necessary for vascular dissemination during late tumor progression and existence of CD9 re-expressing cell clusters mediates the transendothelial invasion of cervical carcinoma cells. Therefore, CD9 may be used as an indicator of a high risk of recurrence in cervical cancer (17). In melanoma, CD9 re-expression was also observed in tumor vessels, suggesting that this protein is involved in tumor angiogenesis and in EC migration (26). It is supposed that CD9, expressed by ECs rather than melanoma cells, is localized at sites of contact between melanoma and ECs. These reports also showed that ECs exhibit an active redistribution of CD9 to points of tumor cell insertion during the extravasation phase of tumor metastasis (27).

The mechanism of the abovementioned role of CD9 is unknown. Klein-Soyer et al highlighted the important role of CD9 in EC migration during lesion repair angiogenesis through cooperation with integrins (28). Recent studies have provided evidence that CD9 hot spots between cells and ECs support not only angiogenesis through in vitro EC migration and invasion induced by vascular endothelial growth factor (VEGF) or hepatocyte growth factor (HGF), but also lymphangiogenesis by interacting with VEGF receptor 3 and integrins in human lymphatic ECs (29,30). Prior to the stage of the CD9 mediating interactions between tumor cells and ECs, matrix metalloproteinases (MMPs) are important in tumor invasion and metastasis. In human melanoma, the CD9 tetracaspain protein appears to contribute to the transendothelial invasion of cancer cells by stimulating MMP-2, which degrades the extracellular matrix (ECM) surrounding ECs (31). In addition to MMP-2, membrane type-1 MMP (MT1-MMP), known as a proinvasive protease during tumor cell invasion, also coimmunoprecipitates and colocalizes with CD9 (32). In addition, invasion and metastasis may be elevated through preventing lysosomal degradation of MT1-MMP by CD9 in cancer cells (33).

In conclusion, we speculate that specific types of tumor expressing high levels of CD9 destroy the ECM through triggering the activity of MMPs, allowing them to contact with vascular ECs. The tumor cells are influenced by cytokines, such as VEGF or HGF, and transmigrate easily through ECs into the circulation.

3. CD9 may enhance tumor cell motility

In the early 1990s, Ikeyama et al introduced a human MRP-1/CD9 complementary DNA plasmid into several cancer cell lines and found the suppression of cell motility following transfection, suggesting that CD9 renders tumor cells more static in vivo, consequently resulting in the suppression of tumor metastasis (8). However, to date, the manner in which CD9 inhibits tumor cell motility remains unclear. Possibly, CD9 hinders metastasis formation by prohibiting integrin-mediated motility of cancer cell lines from lung, breast, skin, gastric, pancreatic and bladder tumors in vitro (34). Other studies have considered that CD9 may downregulate the expression of Wiskott-Aldrich syndrome protein 2 (WAVE2) and that the decreasing WAVE2 then affects the actin cytoskeleton and suppresses tumor cell motility (35,36). Paradoxically, it is increasingly appreciated that CD9 also provides cells with powerful motility in several carcinomas.

Besides promoting metastasis through interaction with ECs, melanoma cells with high levels of CD9 become more motile. In order to understand the expression and function of CD9 in melanoma cells, Fan et al performed an investigation in non-malignant mouse melanocytes, normal human cutaneous melanocytes, B16 mouse melanoma and specific human melanoma cell lines. The authors found that, although CD9 expression is reduced in the transition from melanocytes to melanoma, the re-expression of CD9 in specific melanoma cells alters the microenvironment of the tumor and leads to the enhanced invasion to Matrigel (16).

Detailed studies analyzing CD9 have previously indicated that CD9 alone does not inhibit tumor cell motility. Ganglioside GM3, an important lipid composition of the plasma membrane, cooperatively inhibits haptotactic tumor cell motility through interacting with CD9 (37). However, it has been demonstrated that the motility of tumor cells essentially depends on the expression of GM3. High levels of GM3 expression interacting with high levels of CD9 cooperatively reduces tumor cell motility by inhibiting c-Src activation. Conversely, low GM3 levels but high CD9 levels enhance tumor cell motility through activating c-Src (38). This is why specific tumor cells, expressing higher levels of CD9, are more motile.

CD9 associates with a variety of β integrins (39). Consistent with their previous studies, revealing that ectopic expression of CD9 in a Chinese hamster ovary cell model system causes increased haptotactic motility to ECM proteins (such as fibronectin), Kotha et al demonstrated that CD9, in concert with integrin α5β1, promotes cell motility via a phosphatidylinositol-3 kinase-dependent pathway (40,41). Several lines
of evidence have indicated that integrins are important regulators of cell motility and their dysregulation may be associated with tumor progression (41,42). Pellinen et al identified with loss-of-function and rescue experiments that CD9 activates β1 integrins, which are positively linked with cell motility, such as invasion, in prostate cancer cells (43). Similarly, CD9 also associates with numerous other membrane proteins, such as immunoglobulin protein, in particular microdomains on the plasma membrane. CD9P-1 is a cell surface protein with immunoglobulin domains specifically interacting with CD9. In pathological conditions, such as cancer, the expression levels of CD9 may induce marked effects on cell motility through a change in the membrane compartmentalization of CD9P-1, thus favoring metastasis. Therefore, it has previously been hypothesized that the ratio of expression levels between CD9P-1 and its tetraspanin partners collectively modulates cell motility (44).

CD9 not only promotes the development of bone metastases of MDA-MB-231 breast cancer cells, as previously described, but also enhances the motility of this cell line. Notably, native type IV collagen induces a transient increase of CD9 levels on the surface of MDA-MB-231 breast cancer cells and then increases their motility, such as invasion, through interaction with CD9 (45).

Consequently, we propose that whether CD9 increases the motility or invasion of tumor cells depends on the prevailing conditions, particularly the partner proteins associating with CD9.

**4. CD9 contributes to the proliferation and survival of tumor cells**

A number of previous studies have analyzed the effect of the tetraspanin, CD9, on the life of tumor cells in several types of cancer. For example, Murayama et al described that CD9-mediated apoptosis in human cells is through triggering the activation of c-Jun N-terminal kinase/stress-activated protein kinase and p38 mitogen-activated protein kinases, as well as caspase-3 (46). Zvereff et al elucidated that CD9 interaction with mortalin causes cell death via mitotic catastrophe in prostate cancer cells, showing the importance of CD9 in tumor suppression (47). In addition, Shallal et al found that CD9-transfected myeloma cell lines are more susceptible than control-transfected or non-transfected parental cells to cell-mediated lysis by immune cells (48). By contrast, in specific cases, CD9 appears to enable tumor cells to grow and proliferate more vigorously.

Previously, it has been recognized that heparin-binding epidermal growth factor-like growth factor (HB-EGF) which interacts with CD9 is a membrane-binding cell proliferation factor of the epidermal growth factor (EGF) family and is involved in tumorigenesis and the proliferation of human gastric cancer. A previous study conducted by Murayama et al showed that HB-EGF mRNA levels were higher in gastric cancer than in normal gastric tissues. Subsequently, Hoti et al speculated that CD9 may accelerate the proliferation of gastric cancer cells via interaction with HB-EGF on cell membranes (18,49). A similar phenomenon is also observed in multiple myeloma, that CD9 may increase tumor proliferation through increasing the ability of the HB-EGF/EGF receptor and CD9 may contribute to the proliferation of tumor cells by associating with HB-EGF on cell membranes (50). In addition, myeloma cells with higher levels of CD9 expression proliferate rapidly via interleukin (IL)-16. Since CD9 was reported as an IL-16 receptor, Atanackovic et al proposed that the myeloma cell proliferation may be triggered by IL-16 through interacting with CD9. The authors also speculated that CD9 could be further evaluated as a possible therapeutic target for multiple myeloma in the future (51,52).

Conflicting data exist with regard to CD9 in ovarian cancer. A recent study produced a contradictory result that revealed CD9 to be upregulated in ovarian carcinomas, particularly in serous-type ovarian cancer. In addition, CD9 may function as an antiapoptotic protein through inducing cytokines, such as tumor necrosis factor α, IL-6 and IL-8, as well as constitutively activating the nuclear factor-κB signaling pathway (53).

Tetraspanin CD9 may prevent cancer cells from being killed by chemotherapeutic agents. More recently, Kohmo et al revealed that CD9 is highly re-expressed in small cell lung cancer cells (SCLCs) at relapsed primary tumors and metastasized organs in patients who have received chemotherapy. These recurrent SCLCs appear to be chemoresistant through a cell adhesion-mediated drug resistance mechanism. In addition, selective inhibition of CD9 inducing the apoptosis of chemoresistant SCLC cells implicated that CD9 may serve as a protective factor for SCLCs in ultimately resistant stages (54).
5. CD9 and cancer stem cells (CSCs)

It has been previously reported that tumors may contain CSCs, defined as a small subpopulation exhibiting self-renewal and differentiation abilities. The origin of CSCs is indistinct and some reports have suggested that CSCs may stem from normal tissue stem cells. Thereby, CSCs own similar biological characteristics with normal stem cells and have the potential of initiating tumor development, leading to metastasis and even recurrence.

In normal stem cells, such as mesenchymal stem cells (MSCs), CD9 is important in increasing the MSC proliferation, which has been confirmed by Kim et al. In human testicular germ cell tumors, particularly in intratubular germ cell neoplasia unclassified (IGCNU), CD9 has been deemed a core marker of pluripotent embryonic stem cells and is upregulated. This suggests that CD9 has an underlying impact on the expression of stem cell genes and maintenance of the undifferentiated state in IGCNU. Previously, Nishida et al. performed a comprehensive analysis of surface markers on several B-ALL cell lines and identified that CD9 is a useful positive-selection marker for the identification of CSCs in human B-acute lymphoblastic leukemia and may also serve as a novel therapeutic target in this disease. For the sake of achieving a deeper insight into the CSC properties in CD9-expressing cells of B-ALL cell lines, the authors performed detailed assays and showed that CD9 regulates the cancer-related genes, such as TEL/AML1 and E2A/PBX1, in B-ALL and significantly affects Src family proteins involved in diverse biological functions. Furthermore, CD9+ cells of B-ALL exhibited drug-resistance. Notably, CD9, as a cancer stem cell marker, may also be applied to human malignant mesothelioma.

6. Conclusion

From the abovementioned findings, we conclude that tetraspanin CD9 does not always act as a tumor suppressor. In certain types of carcinoma, CD9 propels tumor progression and metastasis. The underlying mechanisms may involve the following aspects: i) The interaction between CD9 cancer cells and ECs is important in transendothelial migration of the tumor cells; ii) CD9 is likely to enhance the motility, such as invasion, in several types of cancer; iii) CD9 promotes tumor cell growth and prevents apoptosis from chemotherapy drugs; and iv) CD9 is becoming an increasingly important indicator for the identification of CSCs, since CSCs are crucial in oncogenesis. Future studies are required to appreciate the manner in which CD9 contributes to the cancer phenotype.

Acknowledgements

The present study was supported by the Zhejiang Provincial Natural Science Foundation of China (no. R2100213), the National Natural Science Foundation of China (no. 81372622) and the Major Projects in Zhejiang Province (no. 2012C13014-1).

References

1. Zöller M: Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer 9: 40-55, 2009.

2. Romanska HM and Berditschevsky F: Tetraspanins in human epithelial malignancies. J Pathol 223: 4-14, 2011.

3. Hemler ME: Targeting of tetraspanin proteins - potential benefits and drawbacks. Nat Rev Drug Discov 7: 747-758, 2008.

4. Hemler ME: Tetraspanin proteins mediate cellular penetration, invasion and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol 19: 397-422, 2003.

5. Boucheix C and Rubinstein E: Tetraspanins. Cell Mol Life Sci 58: 1189-1205, 2001.

6. Boucheix C, Soriat C, Mirshahi M, et al. Characteristics of platelet aggregation induced by the monoclonal antibody ALB6 (acute lymphoblastic leukemia antigen p 24). Inhibition of aggregation by ALB6Fab. FEBS Lett 161: 289-295, 1983.

7. Kersey JH, LeBien TW, Abramson CS, Newman R, Sutherland R and Greaves M: P-24: a human leukemia-associated lymphohemopoietic progenitor cell surface structure identified with monoclonal antibody. J Exp Med 153: 726-731, 1981.

8. Ikeyama S, Koyama M, Yamaoko M, Sasada R and Miyake M: Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. J Exp Med 177: 1231-1237, 1993.

9. Miyake M, Koyama M, Seno M and Ikeyama S: Identification of the motility-related protein (MRP-1), recognized by monoclonal antibody M5 1-15, which inhibits cell motility. J Exp Med 174: 1343-1354, 1991.

10. Oritani K, Aoyama K, Tomiyama Y, Kincade PW and Matsuzawa Y: Stromal cell CD9 and the differentiation of hematopoietic stem/progenitor cells. Leuk Lymphoma 38: 147-152, 2000.

11. Miyake M, Nakano K, Itai S, Koh T and Taki T: Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer. Cancer Res 56: 1244-1249, 1996.

12. Mori M, Mimori K, Shiraiishi T, et al: Motility related protein 1 (MRP1/CD9) expression in colon cancer. Clin Cancer Res 4: 1507-1510, 1998.

13. Higashiyama M, Doi O, Kodama K, et al: Immunohistochemically detected expression of motility-related protein-1 (MRP-1/CD9) in lung adenocarcinoma and its relation to prognosis. Int J Cancer 74: 205-211, 1997.

14. De Bruyne E, Bos TJ, Assosingh K, et al: Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival. Clin Cancer Res 14: 2918-2926, 2008.

15. De Bruyne E, Andersen TL, De Raeve H, et al: Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine ST333M model and myeloma patients. Leukemia 20: 1870-1879, 2006.

16. Fan J, Zhu GZ and Niles RM: Expression and function of CD9 in melanoma cells. Mol Carcinog 49: 85-93, 2010.

17. Sauer G, Windisch J, Kurzeder C, Heilmann V, Kreienberg R and Deisserth H: Progression of cervical carcinomas is associated with down-regulation of CD9 but strong local re-expression at sites of transendothelial invasion. Clin Cancer Res 9: 6426-6431, 2003.

18. Hori H, Yano S, Koujuki T, Takeda J and Shirozu K: CD9 expression in gastric cancer and its significance. J Surg Res 117: 208-215, 2004.

19. Horváth G, Serru V, Clay D, Billard M, Bouchect C and Rubinstein E: CD9 is linked to the integrin-associated tetraspans CD9, CD81 and CD82. J Biol Chem 276: 4853-4862, 2001.

20. Boucheix C and Rubinstein E: Tetraspanins. Cell Mol Life Sci 19: 397-422, 2003.

21. Sauer G, Windisch J, Kurzeder C, Heilmann V, Kreienberg R and Deisserth H: Progression of cervical carcinomas is associated with down-regulation of CD9 but strong local re-expression at sites of transendothelial invasion. Clin Cancer Res 9: 6426-6431, 2003.

22. Hori H, Yano S, Koujuki T, Takeda J and Shirozu K: CD9 expression in gastric cancer and its significance. J Surg Res 117: 208-215, 2004.

23. Stipp CS, Orlicky D and Hemler ME: FPRP, a major highly stoichiometric, highly specific CD81- and CD9-associated protein. J Biol Chem 273: 1343-1354, 1998.

24. Higashiyama M, Doi O, Kodama K, et al: Immunohistochemically detected expression of motility-related protein-1 (MRP-1/CD9) in lung adenocarcinoma and its relation to prognosis. Int J Cancer 74: 205-211, 1997.

25. De Bruyne E, Bos TJ, Assosingh K, et al: Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival. Clin Cancer Res 14: 2918-2926, 2008.

26. De Bruyne E, Andersen TL, De Raeve H, et al: Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine ST333M model and myeloma patients. Leukemia 20: 1870-1879, 2006.

27. Fan J, Zhu GZ and Niles RM: Expression and function of CD9 in melanoma cells. Mol Carcinog 49: 85-93, 2010.

28. Sauer G, Windisch J, Kurzeder C, Heilmann V, Kreienberg R and Deisserth H: Progression of cervical carcinomas is associated with down-regulation of CD9 but strong local re-expression at sites of transendothelial invasion. Clin Cancer Res 9: 6426-6431, 2003.

29. Hori H, Yano S, Koujuki T, Takeda J and Shirozu K: CD9 expression in gastric cancer and its significance. J Surg Res 117: 208-215, 2004.

30. Horváth G, Serru V, Clay D, Billard M, Bouchect C and Rubinstein E: CD9 is linked to the integrin-associated tetraspans CD9, CD81 and CD82. J Biol Chem 276: 4853-4862, 2001.

31. Boucheix C and Rubinstein E: Tetraspanins. Cell Mol Life Sci 19: 397-422, 2003.

32. Sauer G, Windisch J, Kurzeder C, Heilmann V, Kreienberg R and Deisserth H: Progression of cervical carcinomas is associated with down-regulation of CD9 but strong local re-expression at sites of transendothelial invasion. Clin Cancer Res 9: 6426-6431, 2003.
27. Longo N, Yañez-Mó M, Mittelbrunn M, et al: Regulatory role of tetraspanin CD9 in tumor-endothelial cell interaction during transendothelial invasion of melanoma cells. Blood 98: 3717-3726, 2001.
28. Klein-Soyer C, Azorsa DO, Cazenave JP and Lanza F: CD9 participates in endothelial cell migration during in vitro wound repair. Arterioscler Thromb Vasc Biol 20: 360-369, 2000.
29. Iwasaki T, Takeda Y, Maruyama K, et al: Deletion of tetraspanin CD9 diminishes lymphangiogenesis in vivo and in vitro. J Biol Chem 288: 2118-2131, 2013.
30. Kamissanakuki T, Tokushige S, Terasaki H, et al: Targeting CD9 produces stimulus-independent antiangiogenic effects predominantly in activated endothelial cells during angiogenesis: a novel antiangiogenic therapy. Biochem Biophys Res Commun 413: 128-135, 2011.
31. Hong JK, Kim YM, Jeoung DI, Kim KC and Lee H: Tetraspanin CD9 induces MMP-2 expression by activating p38 MAPK, JNK and c-Jun pathways in human melanoma cells. Exp Mol Med 37: 230-239, 2005.
32. Osenkowski P, Toth M and Fridman R: Processing, shedding and endocytosis of membrane type 1-matrix metalloproteinase (MT1-MMP). J Cell Physiol 200: 2-10, 2004.
33. Laffleur MA, Xu D and Hemler ME: Tetraspanin proteins regulate membrane type-1 matrix metalloproteinase-dependent pericellular proteolysis. Mol Biol Cell 20: 2030-2040, 2009.
34. Richardson MM, Jennings LK and Zhang XA: Tetraspanins and tumor progression. Clin Exp Metastasis 28: 261-270, 2011.
35. Huang CL, Ueno M, Liu D, et al: MRP-1/CD9 gene transduction regulates the actin cytoskeleton through the downregulation of WAVE2. Oncogene 25: 6480-6488, 2006.
36. Takenawa T and Sueatsugu S: The WASP-WAVE protein network: connecting the membrane to the cytoskeleton. Nat Rev Mol Cell Biol 8: 37-48, 2007.
37. Ono M, Handa K, Sonnino S, Withers DA, Nagai H and Hakomori S: GM3 ganglioside inhibits CD9-facilitated haptotactic cell motility: coexpression of GM3 and CD9 is essential in the downregulation of tumor cell motility and malignancy. Biochemistry 40: 6414-6421, 2001.
38. Mitsuzuka K, Handa K, Satoh M, Arai Y and Hakomori S: A specific microdomain (‘glycosynapse 3’) controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of alpha5beta1 integrin with CD9. J Biol Chem 280: 35545-35553, 2005.
39. Rubinstein E, Le Naour F, Billard M, Prenant M and Boucheix C: CD9 antigen is an accessory subunit of the VLA integrin complex. Eur J Immunol 24: 3005-3013, 1994.
40. Kotha J, Longhurst C, Appling W and Jennings LK: Tetraspanin CD9 regulates beta 1 integrin activation and enhances cell motility to fibronectin via a PI-3 kinase-dependent pathway. Exp Cell Res 314: 1811-1822, 2008.
41. Desgrosellier JS and Cheresh DA: Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10: 9-22, 2010.
42. Shattil SJ, Kim C and Ginsberg MH: The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol 11: 288-300, 2010.
43. Pellinen T, Rantalainen J, Arjonen A, Mpindi JP, Kalliomaki O and Ivaska J: A functional genetic screen reveals new regulators of beta1-integrin activity. J Cell Sci 125: 649-661, 2012.
44. Chambrion C and Le Naour F: The tetraspanins CD9 and CD81 regulate CD9PI-induced effects on cell migration. PLoS One 5: e11219, 2010.
45. Castro-Sanchez L, Soto-Guzman A, Navarro-Tito N, Martinez-Orozco R and Salazar EP: Native type IV collagen induces cell migration through a CD9 and DDR1-dependent pathway in MDA-MB-231 breast cancer cells. Eur J Cell Biol 89: 843-852, 2010.
46. Murayama Y, Miyagawa J, Oritani K, et al: CD9-mediated activation of the p46 Shc isoform leads to apoptosis in cancer cells. J Cell Sci 117: 3379-3388, 2004.
47. Zvereff V, Wang JC, Shun K, Lacoste J and Chevrette M: Colocalisation of CD9 and mortalin in CD9-induced mitotic catastrophe in human prostate cancer cells. Br J Cancer 97: 941-948, 2007.
48. Shallal S and Kornbluth J: CD9 expression enhances the susceptibility of myeloma cell lines to cell-mediated cytolysis. Blood 96: 224-233, 2000.
49. Murayama Y, Miyagawa J, Shinomura Y, et al: Significance of the association between heparin-binding epidermal growth factor-like growth factor and CD9 in human gastric cancer. Int J Cancer 98: 505-513, 2002.
50. Murayama Y, Shinomura Y, Oritani K, et al: The tetraspanin CD9 modulates epidermal growth factor receptor signaling in cancer cells. J Cell Physiol 216: 135-143, 2008.
51. Qi JC, Wang J, Mandadi S, et al: Human and mouse mast cells use the tetraspanin CD9 as an alternate interleukin-16 receptor. Blood 107: 135-142, 2006.
52. Atanackovic D, Hildebrandt Y, Templin J, et al: Role of interleukin 16 in multiple myeloma. J Natl Cancer Inst 104: 1005-1020, 2012.
53. Hwang JR, Jo K, Lee Y, Sung BJ, Park YW and Lee JH: Upregulation of CD9 in ovarian cancer is related to the induction of TNF-alpha gene expression and constitutive NF-kappaB activation. Carcinogenesis 33: 77-83, 2012.
54. Kohmo S, Kijima T, Otani Y, et al: Cell surface tetraspanin CD9 mediates chemoresistance in small cell lung cancer. Cancer Res 70: 8025-8035, 2010.
55. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer and cancer stem cells. Nature 414: 105-111, 2001.
56. Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic stem cell. Nat Med 3: 730-737, 1997.
57. Kim YJ, Yu JM, Joo HJ, et al: Role of CD9 in proliferation and proangiogenic action of human adipose-derived mesenchymal stem cells. Pflugers Arch 455: 283-296, 2007.
58. Biermann K, Heukamp LC, Steiger K, et al: Gene expression profiling identifies new biological markers of neoplastic germ cell tumors. Anticancer Res 27: 3091-3100, 2007.
59. Ishida H, Yamazaki H, Yamada T, et al: CD9 correlates with cancer stem cell potentials in human B-acute lymphoblastic leukemia cells. Biochem Biophys Res Commun 382: 57-62, 2009.
60. Yamazaki H, Xu CW, Naito M, et al: Regulation of cancer stem cell properties by CD9 in human B-acute lymphoblastic leukemia. Blood 106: 2307-2316, 2005.
61. Ghani FI, Yamazaki H, Iwata S, et al: Identification of cancer stem cell markers in human malignant mesothelioma cells. Biochem Biophys Res Commun 404: 735-742, 2011.